🇺🇸

US SEC Filing Intelligence

· daily

US Merger & Acquisition SEC Filings — June 26, 2026

The June 26, 2026 US M&A digest reveals a bifurcated SPAC landscape: one new IPO (Texas Ventures IV) successfully launched with $172.5M, while two SPACs (Israel Acquisitions Corp, International Media Acquisition Corp) face existential challenges with deal terminations and repeated extension reliance. The most actionable event is Stratus Properties' $46.5M asset sale as part of its liquidation plan, generating $21.7M in net proceeds for potential shareholder distributions. Two SPACs (Charlton Aria, Willow Lane II, Hall Chadwick) reported only governance or compliance updates with no financial impact. ProAssurance's filing signals a major corporate restructuring or going-private transaction via a dramatic reduction in authorized shares to 2,000. No period-over-period revenue or margin trends were present in these filings, as most are SPACs with no operations. The key theme is capital recycling: Stratus is monetizing assets for liquidation, while SPACs are burning cash on extensions and deal costs.

8 high priority 8 total filings
· daily

US Earnings Financial Results SEC Filings — June 26, 2026

This digest of 30 regulatory filings reveals a bifurcated market where operational improvements for established companies (e.g., Kroger, Korn Ferry) are overshadowed by deepening distress among smaller entities (ZRCN, Beyond Air, VIDA Global) and a cascade of near-zero-materiality Nissan auto trust filings. Period-over-period comparisons show a clear divergence: revenue growth in select industrials (Kewaunee +17.2%, Kinetic Seas +5,000%) contrasts with severe declines at Emerson Radio (-41.5%) and Limitless X (-69%). The most critical developments are for companies on the brink of collapse (NaturalShrimp in liquidation) or in cash-burning growth phases (VIDA, Beyond Air). A recurring pattern of Wilmington Trust litigation introduces latent reputational risk across multiple Nissan securitizations but carries no immediate financial impact. The portfolio-level theme is one of fragility: rapid revenue growth is rarely translating to profitability, margin compression is prevalent even among winners, and insider trading data is notably absent across all 30 filings, removing a key confidence gauge. The first 11 newly published filings, including Kewaunee's margin squeeze despite top-line gains and ZRCN's rapid liquidity deterioration, demand immediate investor attention.

30 high priority 30 total filings
· daily

US Executive Compensation Proxy SEC Filings — June 26, 2026

This digest of 16 proxy filings reveals a period of significant corporate activity, headlined by a transformative acquisition (Electro-Sensors), a major pending merger (Qorvo/Skyworks), and numerous capital structure proposals that pose substantial dilution risks for shareholders of smaller companies. A clear theme is the aggressive use of authorized share increases to facilitate M&A, debt settlement, and financing, particularly at Healthcare Triangle and Zoomcar Holdings, which is a bearish signal for existing equity holders. On the governance front, we see leadership transitions at CorVel and board refreshment at Smucker and Reservoir Media, while Qorvo's low say-on-pay support (59%) signals potential shareholder discontent that has already prompted compensation changes. Financially, Qorvo stands out with a dramatic operational turnaround (gross margin +460 bps YoY, operating income +331%), while most other filers provided no period-over-period financial data, limiting trend analysis. The high concentration of special meetings and shareholder votes in July and August 2026 creates a catalyst-rich calendar for event-driven investors.

16 high priority 16 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 26, 2026

The June 26, 2026 SEC filings reveal a bifurcated IPO/pipeline landscape with three distinct themes: a wave of speculative, high-risk SPAC and micro-cap capital raises targeting digital assets and penny-stock restructuring; a traditional, accretive regional bank merger in the financial sector; and a clinical-stage biotech struggling to stay afloat. Three of the five filers (Professional Diversity Network, Coeptis Therapeutics, and Jupiter Neurosciences) share a common pattern of deep financial distress, with going-concern warnings, chronic net losses, and pivots into unproven or highly volatile asset classes like cryptocurrency mining and tokenization. Meanwhile, AMR Resources Acquisition Corp. represents a blank-check vehicle raising $250M, providing a conduit for private mineral-resource companies to go public, but carries high pre-deal uncertainty. In contrast, Hawthorn Bancshares' bank merger demonstrates tangible pro forma EPS accretion (+2.3% to $3.52) and a clear, cost-synergy-driven integration plan within a stable regulatory framework. The most critical takeaway is that insider activity is absent across all deals, and forward-looking guidance is either nonexistent or heavily caveated, forcing investors to rely on disclosed breakeven thresholds (e.g., Dogecoin price targets) and high-burn-rate timelines as the primary valuation anchors.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — June 26, 2026

The three filings in this digest on trading suspensions, delistings, and regulatory halts reveal a stark bifurcation in micro-cap healthcare and technology companies. Two companies (Upexi and Matinas BioPharma) are actively fighting non-compliance, while one (Outlook Therapeutics) has successfully reversed its delisting risk. The key trend is the high frequency of non-compliance events tied to convertible note structures (Upexi) and sustained negative equity positions (Matinas), which are typical distress signals for micro-caps. Critically, enriched period-over-period data is absent from these filings, as they are event-driven 8-K filings rather than periodic reports; however, forward-looking data on compliance deadlines, insider trading (unavailable), and capital allocation (unavailable) still provides a high-stakes outlook. The most material development is the Russell Microcap Index addition for Upexi, which injects a positive catalyst into an otherwise dire delisting scenario. The sector theme is clear: small-cap biotech and tech firms face a tightening regulatory and capital environment, forcing a high rate of 'penny stock' distress.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 26, 2026

This digest of 42 SEC filings reveals a surge in corporate distress signals, particularly among small-cap life sciences and technology companies. The most critical developments include a Nasdaq delisting notice for Upexi, a second NYSE non-compliance notice for Matinas BioPharma, and a Chapter 11 overbid agreement for Charles & Colvard, indicating severe liquidity crises. A dominant theme is covenant-relief amendments, with Hallador Energy and RMX Industries securing breathing room from lenders, signaling financial strain. Conversely, a wave of opportunistic capital raising is underway, with ADP securing a $5.7B credit facility and Venture Global closing a $1.5B vessel financing, highlighting a bifurcated market where strong companies access cheap capital while distressed firms rely on dilutive or high-cost financing. Insider activity is limited, but the conversion of $4.1M in CEO debt to equity at Veea and the dilutive terms of Cero Therapeutics' note suggest management is using insider structures to manage cash burn. Forward-looking data points to a catalyst-rich period, with key data readouts from Vaxart and a merger deadline for Graf Global approaching in the coming weeks.

42 high priority 42 total filings
· daily

US Corporate Board Director Changes SEC Filings — June 26, 2026

The 39 filings for June 26, 2026, reveal a high volume of board and C-suite transitions, with 12 officer changes (including CFOs at Goodyear, Fortrea, and Premier Air Charter) and 8 director changes, signaling a period of significant leadership restructuring across sectors. A notable trend is the prevalence of 'no disagreement' departures, which may mask underlying strategic shifts or performance pressures. Key period-over-period data from Worthington Enterprises shows a mixed picture: 17% YoY revenue growth but a 210 bps gross margin decline to 27.4%, highlighting margin compression despite top-line expansion. The most critical development is Domo Inc.'s disclosure of 'advanced negotiations around a potential transaction' alongside its CTO resignation, a strong M&A signal. Portfolio-level patterns include a wave of insider retention and incentive awards (StubHub, Hyperliquid, HeartSciences) aimed at locking in key talent amid transitions, and a notable number of spin-off-related appointments (Mobility Global, FedEx Freight), suggesting corporate simplification trends. The overall sentiment is neutral with pockets of mixed signals, requiring investors to scrutinize the quality of leadership changes and underlying financial health.

39 high priority 39 total filings
· daily

USA Insider Trading Pulse — June 26, 2026

This USA Insider Trading Pulse digest for June 26, 2026, reveals a market characterized by significant insider buying at DPC Holdings Ltd, where the CEO and directors collectively invested over $24M at $33.00 per share, signaling strong conviction in the company's prospects. Conversely, a wave of coordinated insider selling at Stevanato Group S.p.A. saw five directors each sell 1,493 shares at $17.09, generating a bearish signal for the stock. A major corporate event at PROASSURANCE CORP resulted in the CEO and other top executives disposing of shares back to the issuer in a buyback/retirement transaction totaling over $15M, which is neutral but significant for capital structure. The day also featured notable open-market sales by a director at COMFORT SYSTEMS USA ($13.1M) and the CFO of Revolution Medicines ($1.6M), both under 10b5-1 plans. Overall, the data shows a split between bullish insider accumulation in select value situations and bearish or neutral dispositions in other names, with a notable absence of forward-looking guidance changes or scheduled events in the filings.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — June 26, 2026

The June 26, 2026, US M&A and takeover landscape is dominated by SPAC activity, with a clear bifurcation between successful capital formation and failed deal execution. Texas Ventures Acquisition IV Corp successfully raised $172.5M in its IPO, signaling continued investor appetite for new SPAC vehicles despite market headwinds. Conversely, Israel Acquisitions Corp terminated its long-pursued business combination with Gadfin Ltd. after multiple amendments, and International Media Acquisition Corp made its 19th trust extension payment, highlighting persistent challenges in consummating deals. In a significant non-SPAC development, Stratus Properties Inc. completed a $46.5M asset sale as part of its approved liquidation plan, generating $21.7M in net proceeds for shareholder distributions. ProAssurance Corp filed a certificate of incorporation reducing authorized shares to just 2,000, strongly suggesting a going-private transaction or major restructuring. The period saw no insider trading activity or forward-looking guidance changes across the filings, but the capital allocation and transaction details provide actionable intelligence on sector trends.

8 high priority 8 total filings
· monthly

US Pre-Market SEC Filings Roundup — June 26, 2026

The overnight filing cycle is dominated by a landmark semiconductor M&A deal and several high-conviction insider transactions, alongside a mixed bag of capital raises and regulatory developments. The $7 billion all-stock acquisition of Synaptics by ON Semiconductor is the standout event, creating a combined entity with $7.8 billion in revenue and a $30 billion TAM expansion, though Onsemi's stock fell ~10% post-announcement, signaling market skepticism on execution risk. Insider activity is a key theme: Kymera Therapeutics' director sold over $23.9 million in stock, while Stellus Capital's director bought shares at a discount, and Navios Maritime's CEO made small, consistent purchases. On the capital front, Forgent Power successfully refinanced $600 million in debt at lower rates, and SK Telecom committed ~$480 million to an AI chip affiliate. However, risks are present: Marti Technologies faces an adverse Turkish court ruling, Domo's CTO resignation amid 'advanced negotiations' for a potential sale raises uncertainty, and SmartKem's massive authorized share increase (from 300M to 5B) signals extreme dilution risk. The period-over-period data from Mizuho shows a 95.2% net income recovery, while Idaho Copper's losses widened 25% YoY, highlighting a bifurcated earnings landscape.

32 high priority 18 medium 50 total filings
· daily

Defense Manufacturing Contracts — June 25, 2026

The single contract in this period, a $538.5M NASA cost-plus incentive fee award to Lockheed Martin for the Low Boom Flight Demonstrator (LBFD), represents a pure civilian R&D program with no direct defense linkage. While the contract signals Lockheed Martin's competitive strength in advanced aircraft manufacturing and provides steady, low-risk cash flow (73% already outlaid), its single-customer, research-focused nature limits revenue visibility and scalability. The highest-conviction signal is neutral-to-bullish given the full-and-open competition win and cost-plus pricing, but the key risk is program termination or budget reallocation post-2026. Investors should watch for milestone achievements and potential contract extensions as catalysts.

1 total filings
· daily

VA Healthcare & Services Contracts — June 25, 2026

This digest covers a single, large civilian contract from the Department of Veterans Affairs (VA) totaling $67.4 million, with zero defense-related exposure. The dominant theme is VA IT infrastructure modernization, specifically through a Service Disabled Veteran Owned Small Business (SDVOSB) set-aside. The highest-conviction signal is neutral: the award to V3GATE, LLC signals strong SDVOSB positioning in VA procurement, but the contract is in its earliest execution stage with only $5,772 outlaid, creating execution risk under a firm-fixed-price structure. Key watch items include revenue recognition pace over the next six months and the likelihood of option exercise, which could expand the total potential value to $263.1 million.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — June 25, 2026

This digest covers a single civilian contract from the Department of Health and Human Services (HHS), specifically the NIH National Cancer Institute (NCI), with a total obligation of $63.1 million awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is a cost-plus-fixed-fee delivery order for R&D facility operations, reflecting a stable but low-margin revenue stream for Leidos. The neutral signal strength (5/10) and low materiality (4/10) indicate this award is not transformative for Leidos, given its one-year performance period and full competition. Key risks include the short duration and lack of option exercise, while the NIH's consistent cancer research funding provides a supportive backdrop for potential follow-on awards.

1 total filings
· daily

New Federal Contractors — June 25, 2026

This digest of 17 new federal contracts, totaling $1.63 billion, reveals a predominantly civilian-driven procurement landscape, with only 3 defense-related awards. The dominant theme is stable, recurring spending by civilian agencies (NASA, Department of State, GSA, VA, Interior, HHS, DOL, Commerce, EPA, DOE, DOT, Treasury) on IT services, logistics, and environmental remediation. The highest-conviction signal is a bullish $125.5M firm-fixed-price contract to Life Science Logistics LLC from GSA for refrigerated warehousing, indicating strong cash flow and potential for margin upside. A key risk is the high number of neutral signals (15 out of 17), reflecting the mature, cost-plus nature of many awards and the early-stage execution of several large contracts, which limits near-term upside surprise for investors.

17 total filings
· daily

Significant Contract Modifications ($10M+) — June 25, 2026

The 17 government contracts analyzed, totaling $1.63 billion in obligations, reveal a predominantly civilian-driven procurement landscape with only 3 defense-related awards. The dominant theme is sustained federal investment in IT services, health IT, and environmental remediation, with NASA's $538.5M Low Boom Flight Demonstrator contract to Lockheed Martin representing the highest-conviction signal due to its cost-plus structure and competitive win. However, the digest is characterized by neutral signals (15 of 17), reflecting mature, low-margin contracts with limited upside surprise. Key risks include concentration in civilian agencies (e.g., Department of the Interior, IRS) and execution risk on fixed-price contracts like Life Science Logistics' $125.5M warehousing deal. Investors should watch for option exercises on the $263.1M VA IT contract to V3GATE and follow-on awards for the Department of Labor's Job Corps program.

17 total filings
· daily

Contract Deobligations Alert — June 25, 2026

This digest of 17 government contracts, with a total obligation of $1.63 billion, reveals a predominantly civilian-driven procurement landscape, with only 3 of the contracts defense-related. NASA and Department of Health/Interior/Treasury agencies dominate the spending. The highest-conviction signal is Life Science Logistics's $125.5M firm-fixed-price award from GSA for pharmaceutical warehousing, which offers strong near-term cash flow ($103M already outlaid) and multi-year revenue visibility ($215.4M potential). A key risk is the heavy concentration of awards nearing completion or in early stages (e.g., V3GATE's VA contract has only $5,772 outlaid), which creates forward revenue uncertainty. The digest shows no clear bearish trend, but execution risk is elevated on several early-stage contracts.

17 total filings
· daily

Contract Option Exercises — June 25, 2026

This digest synthesizes 17 contract option exercises totaling $1.63 billion, dominated by civilian agency awards (14 of 17) with only 3 defense-related contracts. The largest single award is Lockheed Martin's $538.5M NASA Low Boom Flight Demonstrator contract, a neutral-to-bullish signal given its cost-plus structure and 73% completion rate. The highest-conviction bullish signals come from Life Science Logistics' $125.5M GSA refrigerated warehousing contract and ARBOR E & T LLC's $59.8M DOL Job Corps award, both offering predictable, multi-year revenue streams. Key risk: 15 of 17 contracts are rated neutral, reflecting limited transformative revenue visibility across the cohort, with several contracts nearing completion (e.g., ADAMS AND ASSOCIATES at 97% outlayed). Investors should watch for option exercises on the Life Science Logistics and ARBOR E & T contracts as near-term catalysts.

17 total filings
· daily

Federal IT & Cybersecurity Contracts — June 25, 2026

This digest of 6 federal IT and cybersecurity contracts, totaling $464.6 million in obligations, reveals a pronounced civilian agency focus, with only one contract (ManTech's $66.1M DOI award) indirectly supporting defense health IT. The Department of the Treasury (IRS) and Department of Veterans Affairs dominate, accounting for $166.8M combined, signaling sustained investment in legacy IT modernization and endpoint infrastructure. The highest-conviction signal is the V3GATE, LLC $67.4M VA award with a $263.1M ceiling, representing a multi-year growth opportunity for a small SDVOSB in a stable agency budget environment. However, the digest is uniformly neutral (0 bullish, 0 bearish), reflecting early-stage execution risk (V3GATE has only $5,772 outlaid) and fixed-price pricing risk across several contracts. Key watch items include option exercise announcements for V3GATE and LANCER's IRS VMware contract, which will determine revenue durability.

6 total filings
· daily

NASA & Space Contracts Intelligence — June 25, 2026

This digest covers a single $538.5M NASA contract awarded to Lockheed Martin for the Low Boom Flight Demonstrator (LBFD) supersonic research aircraft. The contract is entirely civilian (NASA), with no defense-related obligations, and represents a stable, cost-plus incentive fee arrangement that reduces Lockheed Martin's financial risk. The highest-conviction signal is neutral-to-bullish given the full-and-open competition win and strong execution progress (73% outlaid), but the research-focused nature limits revenue visibility. Key risk is the single-customer concentration and potential budget shifts for supersonic R&D beyond 2026.

1 total filings
· daily

All HHS Contracts — June 25, 2026

The single HHS contract analyzed for June 25, 2026, a $63.1M cost-plus-fixed-fee delivery order awarded to Leidos Biomedical Research Inc. by NIH/NCI for R&D facility operations, is purely civilian, defense-unrelated, and carries a neutral signal (strength 5/10). Revenue is steady but non-transformative for Leidos Holdings, representing approximately 0.1% of annual revenue, with low pricing risk but limited upside given the cost-plus structure and short one-year performance period. The highest-conviction signal is stability in NIH cancer research funding, though the absence of option exercise or follow-on awards introduces revenue discontinuity risk. Key watch item is re-competition timing at NIH NCI for similar GOCO facility operations contracts.

1 total filings